Last reviewed · How we verify
NCT05968651
Social Safety Learning in the Brain Oxytocin System
Phase 2 trial testing Oxytocin nasal spray in Social Phobia in 121 participants. Completed in 30 September 2024.
30 September 2024
Quick facts
| Lead sponsor | University of Washington |
|---|---|
| Phase | Phase 2 |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | double |
| Primary purpose | treatment |
| Enrollment | 121 |
| Start date | 26 June 2023 |
| Primary completion | 30 September 2024 |
| Estimated completion | 30 September 2024 |
| Sites | 1 location across United States |
Drugs / interventions tested
- Oxytocin nasal spray — full drug profile →
Conditions studied
- Social Phobia — all drugs for Social Phobia →
Sponsor
University of Washington
Who can join
Adults 18 to 45, any sex, with Social Phobia. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The investigators are conducting this research study to examine whether oxytocin enhances social safety learning (learning safety through the experience of another individual) in people with social anxiety disorder (SAD) compared to healthy volunteers. Oxytocin is a hormone that can also act as a chemical messenger in the brain. Oxytocin plays a role in a number of functions, including responding to fear and social interactions. In this study, the investigators would like to compare the effects of oxytocin and placebo nasal sprays in adults with SAD and healthy adults. This research study will compare an oxytocin nasal spray to a placebo nasal spray. About 120 people will take part in this research study, all at the University of Washington (UW).
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT05968651
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Oxytocin nasal spray
Trials testing the same drug.
- NCT07162584 — Oxytocin and Human Defensive Responses in a Dynamic Situation · NA · recruiting
- NCT06194851 — Examining Intranasal Oxytocin Augmentation of Brief Couples Therapy for Veterans With PTSD · Phase 2 · recruiting
- NCT05934812 — Intranasal Oxytocin in Youth With Autism · Phase 2 · not yet recruiting
- NCT06881810 — Enhancing Social Skills in Schizophrenia Spectrum Disorders - Oxytocin as add-on to Psychosocial Treatment · Phase 2 · recruiting
- NCT06332066 — Oxytocin Administration to Therapists and Its Effects on Patient-perceived Attunement and Responsiveness · Phase 1 · unknown
Other recruiting trials for Social Phobia
Currently open trials in the same condition.
- NCT06564402 — Augmentation of Exposure Using Positive Mental Rehearsal in Individuals With Increased Social Anxiety · NA · recruiting
Other University of Washington trials
Trials by the same sponsor.
- NCT07430852 — Inherited and Environmental Risks Acting on Body Weight · NA · not yet recruiting
- NCT07466498 — Estrogen to Improve Quality of Life for Men With Newly Diagnosed or Recurrent Metastatic Hormone Sensitive Prostate Canc · Phase 2 · not yet recruiting
- NCT06422299 — Developing and Testing an Online Intervention for Alcohol and Cannabis Misuse and Healthy Relationship Skills Among Youn · NA · not yet recruiting
- NCT07322341 — SX-682 and Atezolizumab for the Treatment of Advanced or Metastatic, Recurrent Non-small Cell Lung Cancer · Phase 2 · not yet recruiting
- NCT07332351 — Neoadjuvant Intravesical Nadofaragene Firadenovec With Gemcitabine, Cisplatin and Durvalumab for the Treatment of Muscle · Phase 2 · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05968651 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by University of Washington
- Last refreshed: 13 December 2024
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05968651.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing